UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q __________________________________________________ (Mark One) Washington, DC 20549 __________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36327 ________ ...

Corporate Presentation August 2022 © Neoleukin Therapeutics. All Rights Reserved. Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulato ...

Neoleukin Therapeutics, Inc. (NLTX) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor Relations Jonathan Drachman - Chief Executive Officer Priti Patel - Chief Medical Officer Sean Smith - Vice President, Finance Conference Call Participants Mary Kate - Bank of America Charles Zhu - Guggenheim Securities Ben Burnett - Stifel Mara Goldstein - Mizuho Securities Operator Good afternoon and thank you for joining us today for the Neoleukin Therapeutics Confe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36327 _____________ ...

Corporate Presentation May 2022 @Neoleukin Therapeutics. All Rights Reserved. Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory r ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Se ...

Neoleukin Therapeutics, Inc. (NLTX) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Julie Rathbun - Communications, Investor Relations Jonathan Drachman - CEO Priti Patel - CMO Sean Smith - Vice President, Finance Conference Call Participants Mary Kate - Bank of America Joe Catanzaro - Piper Sandler Charles Zhu - Guggenheim Mara Goldstein - Mizuho Operator Good afternoon and thank you for joining us today for Neoleukin Therapeutics Conference Call. At this time, all participan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36327 _________________________ Neoleukin Therapeutics, Inc. ( ...

neoleukin" Corporate Presentation November 2021 Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36327 ________ ...